These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25645843)

  • 1. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2299-304. PubMed ID: 25645843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
    Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Schuck VJ; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):368-75. PubMed ID: 26525790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the post-antibiotic effect
    Berkhout J; Melchers MJ; van Mil AC; Lagarde CM; Nichols WW; Mouton JW
    J Chemother; 2021 Oct; 33(6):400-408. PubMed ID: 33682636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.
    Housman ST; Crandon JL; Nichols WW; Nicolau DP
    Antimicrob Agents Chemother; 2014; 58(3):1365-71. PubMed ID: 24342641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.
    Nicolau DP; Siew L; Armstrong J; Li J; Edeki T; Learoyd M; Das S
    J Antimicrob Chemother; 2015 Oct; 70(10):2862-9. PubMed ID: 26133566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.
    Sy SKB; Zhuang L; Xia H; Beaudoin ME; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2018 May; 73(5):1295-1304. PubMed ID: 29415212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime.
    Giri P; Patel H; Srinivas NR
    Drug Res (Stuttg); 2019 May; 69(5):245-255. PubMed ID: 30296806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
    Sy SKB; Zhuang L; Sy S; Derendorf H
    Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers.
    Dimelow R; Wright JG; MacPherson M; Newell P; Das S
    Drugs R D; 2018 Sep; 18(3):221-230. PubMed ID: 30054895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
    Merdjan H; Rangaraju M; Tarral A
    Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
    Merdjan H; Tarral A; Das S; Li J
    J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).
    Nichols WW; Bradford PA; Stone GG
    J Antimicrob Chemother; 2022 Aug; 77(9):2341-2352. PubMed ID: 35660869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.
    Crandon JL; Schuck VJ; Banevicius MA; Beaudoin ME; Nichols WW; Tanudra MA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6137-46. PubMed ID: 22985878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.